Please assess the completion status of the following clinical trial:

Trial Title: Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant or lactating female, 18-50 years of age inclusive~2. Patients must have exhibited symptoms meeting the criteria of schizophrenia for at least one year, but not more than 20 years, prior to Screening~3. Recent onset (not more than 30 days) of worsening of psychiatric symptoms at Screening.~4. Currently experiencing an acute exacerbation of schizophrenia, as defined by the following results at Screening and Baseline:~   * ≥70 total score on the PANSS~  * ≥4 (moderate) on two of the following four PANSS items: (1) delusions, (2) hallucinatory behaviors, (3) conceptual disorganization or (4) suspiciousness/persecution, where at least one of the two items must be either delusions or hallucinatory behaviors~5. CGI-S score between 4 and 6 (moderately ill to severely ill) at the Screening and Baseline visits.~6. Has exhibited a sufficient clinical response to at least one previous course of an anti-psychotic agent prescribed at a generally recognized therapeutic dose.~7. Must have completed at least 5 years of formal education or its equivalent~Exclusion Criteria:~1. Breastfeeding or pregnant~2. Symptoms of schizophrenia for more than 20 years at the time of screening.~3. Psychotic symptoms that have failed to improve (based on Investigator's opinion or documented medical history) following sufficient treatment with therapeutic doses of two or more anti-psychotics agents over the preceding 2 years~4. Prior history of neuroleptic malignant syndrome~5. Prior history or current evidence of moderate or severe tardive dyskinesia (mild is acceptable).~6. Abnormal ECG evaluation~7. History of confirmed epilepsy or prior seizure disorder (history of a single febrile seizure is not exclusionary)~8. In the opinion of the investigator, unstable medical disease (e.g., malignancy, poorly controlled diabetes or hypertension, ischemic cardiac disease, dilated cardiomyopathy or valvular heart disease, pulmonary disease, liver disease, kidney disease)~9. Acute infectious disease (e.g., malaria, dengue fever, hepatitis A), or chronic infectious disease (e.g., history of AIDS or HIV positivity, tuberculosis)~10. Likely allergy, sensitivity or intolerance to BL-1020, perphenazine, risperidone, paliperidone, or any of the drug product excipients~11. Any suicide attempt within the preceding 2 years~12. Any Substance Dependence disorder~13. High likelihood of substance abuse~14. Diagnosis with one of the following DSM-IV-TR Axis I diagnoses: schizophreniform disorder, schizoaffective disorder, bipolar disorder, substance dependency, mood disorder with psychotic features; psychotic disorder NOS~15. Requiring chronic treatment with benzodiazepines~16. Requiring chronic treatment with mood stabilizers~17. Previously treated with clozapine within 6 months prior to screening~18. Any abnormal clinical laboratory test result that is judged by the Investigator to be clinically significant~19. History of, or serologic evidence of, acute or chronic active hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- CYP-1020 (Type: EXPERIMENTAL): Dose titration 15-35mg/day for 6 months
- Risperidone (Type: ACTIVE_COMPARATOR): Dose titration 2-6mg/day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy